Intercept Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Intercept Pharmaceuticals balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Intercept Pharmaceuticals cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Intercept Pharmaceuticals multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Intercept Pharmaceuticals profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Intercept Pharmaceuticals assets
Intercept Pharmaceuticals cash flows
Intercept Pharmaceuticals news
06.05.2022
Intercept Pharmaceuticals' GAAP loss for 3 months of 2022 was $17.284 million, down 2.4 times from $40.42 million in the previous year. Revenue increased 8.5% to $88.582 million from $81.661 million a year earlier.
Source: {source} pictogram ir.interceptpharma.com
Pictogram next
02.03.2022
Intercept Pharmaceuticals' GAAP loss for 2021 was $91.426 million, down 3 times from $274.88 million in the previous year. Revenue increased 16.2% to $363.468 million from $312.69 million a year earlier.
Source: {source} pictogram ir.interceptpharma.com
Pictogram next
03.11.2021
Intercept Pharmaceuticals' GAAP loss for 9M 2021 was $55.146 million, down 4.5 times from $222.733 million in the previous year. Revenue increased 18.2% to $271.064 million from $229.422 million a year earlier.
Source: {source} pictogram ir.interceptpharma.com
Pictogram next
29.07.2021
Intercept Pharmaceuticals' GAAP loss for the six months of 2021 was $51.514 million, down 3.1 times from $156.264 million in the previous year. Revenue increased 18.9% to $178.237 million from $149.901 million a year earlier.
Source: {source} pictogram ir.interceptpharma.com
Pictogram next
All Intercept Pharmaceuticals news
General information
Company nameIntercept Pharmaceuticals
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address10 HUDSON YARDS, 37TH FLOOR NEW YORK NY 10001 646-747-1000
Mailing address10 HUDSON YARDS, 37TH FLOOR New York NY 10001
Websitewww.interceptpharma.com
Information disclosurewww.sec.gov